secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2022-02-23T23:59:59+00:00
Accession:  0001193125-22-050174
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adagio CEO Tillman Gerngross resigns; COO David Hering appointed interim CEO
----------------------------------------------------------------------------

- David Hering appointed interim CEO, effective immediately; will also remain Chief Operating Officer.
- Board initiated a formal CEO search for a candidate with commercial-stage experience.
- Outgoing CEO Tillman Gerngross co-founded company, raised over $800M, advanced ADG20 into global pivotal trials for COVID-19.
- Hering previously led Pfizer's mRNA global franchise and was President of North America Vaccines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312522050174/0001193125-22-050174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312522050174/d267907d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-050174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer